Seattle Startup Cajal Neuroscience Raises $96M to Develop New Alzheimer's and Parkinson's Treatments

Seattle-based startup Cajal Neuroscience, founded in 2020, has raised $96 million to develop treatments for neurodegenerative diseases like Alzheimer's and Parkinson's by exploring diverse drug targets beyond amyloid-beta. The company aims to understand genetic variants' roles in disease mechanisms to identify key molecules involved in neurodegeneration.